


NEW SYNTHESIS OF THIENO[3,2-c]PYRIDINES

Jean-Pierre MAFFRAND<sup>\*\*</sup> and Robert BOIGEGRAIN


PARCOR Département Recherche & Développement, 195, route d'Espagne,  
31024-TOULOUSE CEDEX FRANCE

**Abstract** - A new synthesis of thieno[3,2-c]pyridines by thermal rearrangement of 5-(2-thienyl)oxazolidines is described.

Ticlopidine (1), a new potent blood platelet aggregation inhibitor and antithrombotic agent<sup>1</sup>, was synthesized from thieno[3,2-c]pyridine itself (2) or its tetrahydrogenated derivative (3)<sup>2</sup> by the following reactions:



An other route to (1)<sup>3</sup> resulted from an application of Bobbitt's<sup>4</sup> improvement of the general Pomeranz-Fritsch isoquinolines synthesis<sup>5</sup> (scheme II).



In this process, the formation of the aminoacetal intermediate (5) required the use of an expensive material, 3-thienaldehyde.

We wish now to report the synthesis of the intermediate hydroxy derivative (13a) starting from 2-thienaldehyde as well as a new process for the preparation of 2-substituted thieno[3,2-c]pyridines.


In 1962, Corey and Chaykovsky<sup>6</sup> realized the transformation of aldehydes and ketones into oxiranes by treatment with the sulfur ylid obtained by reacting trimethylsulfonium iodide with dimethylsodium in a tetrahydrofuran-dimethylsulfoxide solution.

It has been shown recently<sup>7</sup> that the same ylid could be generated in a biphasic system (50% sodium hydroxide solution-methylenechloride) in the presence of tetrabutylammonium iodide as phase transfer catalyst.

Such a process was convenient for the synthesis of styrene oxide (92%) but failed in our hands to produce 2-thienyloxirane from 2-thienaldehyde.

However, this reaction succeeded when carried out by using a long chain alkylated sulfonium salt without phase transfer catalyst according to Tagaki and coll.<sup>8</sup> Accordingly, epoxides (9a-c) were easily obtained from thienaldehydes (8a-c) and dodecyldimethyl sulfonium methylsulfate<sup>9</sup> (scheme III).

SCHEME III



Among these compounds only (9a) had been previously prepared<sup>10</sup> from 2-chloro 1-(2-thienyl)ethanol. The oxirane ring opening with an excess of o-chlorobenzylamine at room temperature led to

a mixture of amino alcohols (10) and (11) from which (11) was isolated by fractionated crystallization. The treatment of oxiranes with other amines<sup>9</sup> allowed the preparation of amino alcohols analogs to (11), some of which had been previously described<sup>11</sup>.

By condensation with formaldehyde in 40 % aqueous solution, (11a-c) gave the corresponding oxazolidines (12a-c); their hydrochlorides were thermically rearranged to thienopyridines (13a-c) by refluxing in toluene or diisopropylether; this rearrangement was similar to that described by Kametani and coll.<sup>12</sup> for the preparation of isoquinolines.

Dehydroxylation of (13b) and (13c) with stannous chloride-hydrochloric acid in acetic acid gave the Ticlopidine analogs (14b) and (14c). The 2-chloro derivative (14c) was also obtained by direct chlorination of (1) with sulfuryl chloride according to the Godt and Wann process<sup>13</sup> used for the synthesis of other thiophen derivatives. Amino alcohols (13a-c) were also useful intermediates to the new corresponding thieno[3,2-c]pyridines (16a-c).

N-Bromosuccinimide oxidation of (13a-c) in chloroform at room temperature yielded (15a-c) which were immediately transformed into (16a-c) by heating at 120°C in dimethylformamide in the presence of 1,4-diazabicyclo[2.2.1]octane: indeed both reactions, the expected dequaternisation<sup>14</sup> and the dehydration, simultaneously occurred. It was shown that the conversion of (15a) into (16a) could be carried out in two steps by dehydration with acetic anhydride followed by dequaternisation with DABCO in dimethylformamide.

| N°  | mp or<br>bp/mmHg (°C)                                 | Yield<br>% | <sup>1</sup> H. N.M.R. (ppm)  |
|-----|---|------------|---|
| 13a | 199 - 201<br>(EtOH)                                   | 93         | CDCl <sub>3</sub> : 3,45(q,J=14;2); 3,75(s;2); 4,65(t;1);<br>6,85(q,J=5,5;2)                |
| 13b | 189 - 191<br>(EtOH)                                   | 92         | CDCl <sub>3</sub> : 2,40(s;3); 3,45(q,J=14;2); 3,75(s;2);<br>4,60(t;1); 6,30(s;1)           |
| 13c | 179 - 181<br>(EtOH)                                   | 82         | CDCl <sub>3</sub> : 3,40(q,J=14;2); 3,75(s;2); 4,55(t;1);<br>6,40(s;1)                      |
| 14b | hydrochloride<br>188 - 190<br>(iPrOH)                 | 63         | CDCl <sub>3</sub> : hydrochloride: 2,35(s;3); 4,15(s;2);<br>4,60(s;2); 6,35(s;1); 7,40(s;4) |
| 14c | hydrochloride<br>208 - 210<br>(EtOH/H <sub>2</sub> O) | 60         | CDCl <sub>3</sub> : 2,75(s;4); 3,45(s;2); 3,75(s;2);<br>6,45(s;1)                           |
| 15a | 162-164<br>(EtOH)                                     | 56         | (DMSO d <sub>6</sub> ): 4,10(m;2); 5,40(t;1); 5,45(s;2);<br>7,75(q,J=5,5;2); 9,75(s;1)      |
| 15c | 185 - 187<br>(EtOH)                                   | 89         | (DMSO d <sub>6</sub> ): 4,10(m;2); 5,30(t;1); 5,45(s;2);<br>9,55(s;1)                       |
| 16a | 47 - 49   | 60         | litt. (15)  |
| 16b | hydrochloride<br>189 - 191<br>(EtOH)                  | 58         | CDCl <sub>3</sub> : 2,45(s;3); 6,85(s;1); 7,55(d,J=5,5;1);<br>8,30(d,J=5,5;1); 8,85(s;1)    |
| 16c | 85 - 86 /0,1<br>45 - 46                               | 54         | CDCl <sub>3</sub> : 7,10(s;1); 7,50(d,J=5,5;1); 8,30(s,J=5,5;1);<br>8,80(s;1)               |
| 17a | 201 - 203<br>(iPrOH)                                  | 64         | (DMSO d <sub>6</sub> ): 6,25(s;2); 8,25(q,J=5,5;2); 9,00(s;2);<br>10,05(s;1)                |

<sup>15b</sup> was not isolated

ACKNOWLEDGEMENT Mrs Marguerite Miquel, Andrée Saint-Blancat and Mr Alain Badorc rendered skilful technical assistance.

REFERENCES

- 1 M. Podesta, D. Aubert and J.C. Ferrand, Eur. J. Med. Chem., 1974, 9, 487.  
J.J. Thebault, C.E. Blatrix, J.F. Blanchard and E.A. Panak, Clin. Pharmacol. Ther., 1975, 18, 485
- 2 J.P. Maffrand and F. Eloy, Eur. J. Med. Chem., 1974, 9, 483.
- 3 J.P. Maffrand and F. Eloy, J. Heterocyclic Chem., 1976, 13, 1347.
- 4 J.M. Bobbitt, Adv. Heterocyclic Chem., 1973, 15, 99.
- 5 W.J. Gensler, Organic Reactions, 1951, vol. VI, J. Willey, New York, 191.
- 6 E.J. Corey and M. Chaykovsky, J. Am. Chem. Soc., 1962, 84, 3782.  
E.J. Corey and M. Chaykovsky, ibid., 1965, 87, 1353.
- 7 A. Merz and G. Märkt, Angew. Chem. (Engl), 1973, 12, 845.
- 8 Y. Yano, T. Okonogi, M. Simaga and W. Tagaki, J. Chem. Soc. Chem. Comm., 1973, 527.
- 9 R. Boigegrain and J.P. Maffrand, Brevet Français, 1978, 78, 12037.
- 10 H. Hopff and R. Wandeler, Helv. Chim. Acta, 1962, 45, 983.
- 11 C. Corral, V. Darias, M.P. Fernandez-Tome, R. Madroñero and J. del Rio, J. Med. Chem., 1973, 16, 882.  
J.F. Bagli and E. Ferdinandi, Can. J. Chem., 1975, 53, 2598.  
J.F. Bagli, W.D. Mackay, E. Ferdinandi, M.N. Cayen, I. Vavra, Th. Pugsley and W. Lippman, J. Med. Chem., 1976, 19, 876.
- 12 T. Kametani, K. Kigasawa, M. Hiragi and H. Ishimaru, Chem. Pharm. Bull. (Tokyo), 1969, 17, 2353.
- 13 H.C. Godt and R.E. Wann, J. Org. Chem., 1962, 27, 1459.
- 14 T.L. Ho, Synthesis, 1972, 12, 702.  
T.L. Ho, Synthetic. Comm., 1973, 3, (2), 99.
- 15 S. Gronowitz and E. Sandberg, Arkiv. Kemi., 1970, 32, 269

Received, 10th July, 1979